Patients with EGFR/ALK wild‐type metastatic NSCLC and without disease progression (PD) in the initial treatment were randomly assigned to receive durvalumab combined with olaparib or durvalumab monotherapy as first‐line treatment. Here, EGFR is linked to non-small cell lung carcinoma.